Chemotherapy News and Research

Latest Chemotherapy News and Research

Scientists combine new type of nanoparticle with photodynamic therapy to kill cancer cells

An international group of scientists led by Gang Han, PhD, at the University of Massachusetts Medical School, has combined a new type of nanoparticle with an FDA-approved photodynamic therapy to effectively kill deep-set cancer cells in vivo with minimal damage to surrounding tissue and fewer side effects than chemotherapy. This promising new treatment strategy could expand the current use of photodynamic therapies to access deep-set cancer tumors.

16 Oct 2014

Penn Medicine announces recipients of new Basser External Research Grant Program

The University of Pennsylvania's Basser Research Center for BRCA has announced $6.9 million to research teams both at Penn and at five other institutions across the United States, aimed at advancing the care of patients living with BRCA1 and BRCA2 mutations through multi-disciplinary collaboration.

15 Oct 2014

New technique for treating eye cancer retinoblastoma

Doctors at Cincinnati Children's Hospital Medical Center have developed a new technique for treating the eye cancer retinoblastoma to improve the odds for preventing eye loss, blindness or death in children with advanced forms of the disease.

14 Oct 2014

Gene in soil-dwelling amoeba may hold key to isolating cancerous tumors

The dirt in your backyard may hold the key to isolating cancerous tumors and to potential new treatments for a host of cancers.

14 Oct 2014

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

13 Oct 2014

NCCN publishes 20th annual editions of NCCN Guidelines for Colon and Rectal Cancers

The National Comprehensive Cancer Network has published the 20th annual editions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon and Rectal Cancers, two of the eight original NCCN Guidelines published in November 1996.

10 Oct 2014

Discovery may provide new therapeutic avenue to target autophagy in tumors

No matter what type of chemotherapy you attack a tumor with, many cancer cells resort to the same survival tactic: They start eating themselves.

10 Oct 2014

VAL-083 drug compound shows promise against non-small cell lung cancer

DelMar Pharmaceuticals, Inc., a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai.

9 Oct 2014

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors.

9 Oct 2014

Tel Aviv University researcher advances novel strategy to fight cancer by shoring up the immune system

Two years ago, Prof. Eshel Ben-Jacob of Tel Aviv University's School of Physics and Astronomy and Rice University's Center for Theoretical Biological Physics made the startling discovery that cancer, like an enemy hacker in cyberspace, targets the body's communication network to inflict widespread damage on the entire system.

8 Oct 2014

Research finding could potentially lead to new strategies to improve cancer therapies

Cells are generally able to repair spontaneous damage that arises in their genetic material. Unfortunately, the DNA repair process is not perfect and sometimes, damaged DNA gets passed on to newly made cells. A team of researchers at the Center for Molecular Biology of Heidelberg University has recently discovered that in yeast cells, the amount of nutrients that cells are exposed to can affect DNA surveillance and repair mechanisms and therefore the quality of their DNA.

8 Oct 2014

Cyclophosphamide drug can eliminate life-threatening immune response after bone marrow transplants

Johns Hopkins and other cancer researchers report that a very short course of a chemotherapy drug, called cyclophosphamide, not only can prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate such patients' need for the usual six months of immune suppression medicines commonly prescribed to prevent severe forms of this immune response.

8 Oct 2014

'Achilles heel' in metabolic pathway could stop growth of lung cancer cells

Researchers at UT Southwestern Medical Center have found an "Achilles heel" in a metabolic pathway crucial to stopping the growth of lung cancer cells.

8 Oct 2014

UC Irvine scientist receives New Innovator Award to create stem cell-based treatments for cancer

UC Irvine scientist Weian Zhao will receive a prestigious National Institutes of Health Director's New Innovator Award to further his efforts to create stem cell-based detection methods and treatments for cancer.

7 Oct 2014

Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours after surgery).

7 Oct 2014

FDA grants orphan drug designation for neuroblastoma vaccine

The U.S. Food and Drug Administration granted orphan drug designation for a neuroblastoma vaccine from MabVax Therapeutics, providing development incentive with market exclusivity of the novel treatment for children with this deadly childhood cancer.

6 Oct 2014

CTRC researcher receives special $1.62 million orphan disease grant from FDA

A researcher at the Cancer Therapy & Research Center is the leader on a study receiving a special $1.62 million orphan disease grant from the Food & Drug Administration.

5 Oct 2014

IRCM researchers discover mechanism that promotes progression of medulloblastoma

Scientists at the IRCM discovered a mechanism that promotes the progression of medulloblastoma, the most common brain tumour found in children. The team, led by Fr-d-ric Charron, PhD, found that a protein known as Sonic Hedgehog induces DNA damage, which causes the cancer to develop.

3 Oct 2014

Genoscience Pharma to present novel cancer therapeutic strategy at EORTC-NCI-AACR Symposium

Genoscience Pharma, a company focused on discovering and developing small molecules to treat cancer by targeting cancer stem cells, today announces that it will present data on its most promising candidate at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona, Spain, on November 18-21, 2014.

3 Oct 2014

State highlights: Fla. toughens drug compounding laws; Conn. hospitals leave largest insurer

A selection of health policy stories from Florida, Connecticut, New York, Michigan, Louisiana, Pennsylvania and Arkansas.

1 Oct 2014

Chemotherapy News and Research

Latest Chemotherapy News and Research

Scientists combine new type of nanoparticle with photodynamic therapy to kill cancer cells

Penn Medicine announces recipients of new Basser External Research Grant Program

New technique for treating eye cancer retinoblastoma

Gene in soil-dwelling amoeba may hold key to isolating cancerous tumors

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

NCCN publishes 20th annual editions of NCCN Guidelines for Colon and Rectal Cancers

Discovery may provide new therapeutic avenue to target autophagy in tumors

VAL-083 drug compound shows promise against non-small cell lung cancer

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

Tel Aviv University researcher advances novel strategy to fight cancer by shoring up the immune system

Research finding could potentially lead to new strategies to improve cancer therapies

Cyclophosphamide drug can eliminate life-threatening immune response after bone marrow transplants

'Achilles heel' in metabolic pathway could stop growth of lung cancer cells

UC Irvine scientist receives New Innovator Award to create stem cell-based treatments for cancer

Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

FDA grants orphan drug designation for neuroblastoma vaccine

CTRC researcher receives special $1.62 million orphan disease grant from FDA

IRCM researchers discover mechanism that promotes progression of medulloblastoma

Genoscience Pharma to present novel cancer therapeutic strategy at EORTC-NCI-AACR Symposium

State highlights: Fla. toughens drug compounding laws; Conn. hospitals leave largest insurer

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in